 |
|
Inhibition of Intimal Hyperplasia Using the Selective Estrogen Receptor Modulator Raloxifene
Craig H. Selzman, MD;
A. Simon Turner, BVSc;
Jaime S. Gaynor, DVM;
Stephanie A. Miller, MD;
Eric Monnet, DVM;
Alden H. Harken, MD
Arch Surg. 2002;137:333-336.
Hypothesis The selective estrogen receptor modulator raloxifene hydrochloride inhibits intimal hyperplasia.
Design Controlled laboratory experiment.
Setting Experimental animal model.
Intervention and Main Outcome Measures Forty-three senile female sheep were randomized to sham operation, ovariectomy, or ovariectomy followed by treatment with 17 -estradiol or raloxifene. Six months after initial operation, we performed necropsy with histological assessment of the aortic bifurcation and bone mineral densitometry and assayed serum lipids.
Results After 6 months, serum triglyceride and total and high-density lipoprotein cholesterol levels were similar among groups and within the reference range. Ovarian ablation alone resulted in intimal hyperplasia, which was attenuated with estradiol and raloxifene therapy. Furthermore, estradiol and raloxifene therapy reversed ovariectomy-induced decreases in bone mineral density measured using spine morphometry.
Conclusions Raloxifene attenuates ovariectomy-induced aortic intimal hyperplasia independent of serum lipid levels. These data suggest that raloxifene, in addition to its beneficial influence on bone density, has direct, beneficial cardiovascular effects.
From the Division of Cardiothoracic Surgery, Department of Surgery, University of Colorado Health Sciences Center, Denver (Drs Selzman, Miller, and Harken) and the College of Veterinary Medicine, Colorado State University, Fort Collins (Drs Turner, Gaynor, and Monnet).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Deleterious effects of endogenous and exogenous testosterone on mesenchymal stem cell VEGF production
Ray et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008;294:R1498-R1503.
ABSTRACT
| FULL TEXT
|
